Trial Profile
A multicentre, multinational, randomised, open study to establish the optimal method for initiating Lantus (insulin glargine) therapy to determine metabolic and economic outcomes, safety, and satisfaction in subjects with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2018
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms INITIATE
- Sponsors Sanofi
- 01 Apr 2018 Results of pooled analysis of Asian patients included in this and other six trials assessing the impact of patient baseline covariates on the required dose of basal insulin and treatment response for the improved management of Asian patients with type 2 diabetes published in the Diabetes Therapy
- 18 Jul 2007 Status change
- 25 Apr 2007 New trial record.